{"id":"W3131487333","doi":"10.1016/j.msard.2021.102844","title":"Ozanimod in relapsing multiple sclerosis: Pooled safety results from the clinical development program","year":2021,"lang":"en","type":"article","venue":"Multiple Sclerosis and Related Disorders","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University; NeuroRx Research (Canada); Montreal Neurological Institute and Hospital","funders":"Sanofi Genzyme; Allergan; EMD Serono; MedDay Pharmaceuticals; Innosuisse - Schweizerische Agentur für Innovationsförderung; Schweizerische Multiple Sklerose Gesellschaft; Eisai; Alexion Pharmaceuticals; Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung; Multiple Sclerosis Society; Ministerstvo Školství, Mládeže a Tělovýchovy; Atara Biotherapeutics; Mylan; Baxalta; TG Therapeutics; National Research Foundation; F. Hoffmann-La Roche; Novartis; Celgene; Bayer; Pfizer; Biogen; Roche; Teva Pharmaceutical Industries; Bayer HealthCare; European Commission; Multiple Sclerosis International Federation; Sanofi; Genentech; National Multiple Sclerosis Society; Merck; CSL Behring; Bristol-Myers Squibb","keywords":"Medicine; Internal medicine; MedDRA; Population; Adverse effect; Placebo; Clinical trial; Incidence (geometry); Phases of clinical research; Pathology; Pharmacovigilance","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001999764,0.0005923939,0.001075524,0.0001707758,0.0009003007,0.0001768878,0.0003246473,0.0005779684,0.00009760161],"category_scores_gemma":[0.007647123,0.0004292786,0.0003972374,0.001135359,0.0007125281,0.0002130416,0.0006513299,0.001594026,0.00006877775],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002235759,"about_ca_system_score_gemma":0.0004363394,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001153102,"about_ca_topic_score_gemma":0.006547848,"domain_scores_codex":[0.9934587,0.0007753646,0.002213406,0.001543546,0.0009108805,0.00109811],"domain_scores_gemma":[0.9948754,0.003018677,0.0003487421,0.0009852051,0.0003054023,0.000466576],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.002551942,0.002668098,0.3790484,0.00005649212,0.0009968074,0.00003142771,0.004161922,0.0001510225,0.00553243,0.00001096481,0.001856631,0.6029339],"study_design_scores_gemma":[0.02719602,0.0002076332,0.9427237,0.002080323,0.0001568848,0.000004892056,0.003544779,0.007474152,0.0005636177,0.00003889984,0.01549626,0.0005128435],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9762238,0.008707675,0.00005454823,0.009704413,0.0007334454,0.002471221,0.0001243204,0.0003266737,0.001653948],"genre_scores_gemma":[0.961123,0.03085778,0.006293359,0.0004233897,0.0001164466,0.0002528209,0.0004989777,0.00009294907,0.000341308],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.602421,"threshold_uncertainty_score":0.9998159,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08706421045346827,"score_gpt":0.316655371971675,"score_spread":0.2295911615182067,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}